Should Your Next Oncology Trial Be Decentralized?

Across a range of therapeutic areas, decentralized clinical trial (DCT) approaches allow high-quality data to be collected at participants’ homes rather than exclusively at sites, making involvement more inclusive and participant-centric.

The use of DCT approaches in oncology studies is on the rise but is in the early stages despite the fact that (as of 2019), there have been just over 361,000 oncology studies since 2000, approximately 300,000 more than the second most commonly studied therapeutic area (cardiovascular diseases). This may be attributed to the limited guidance that currently exists on how the spectrum of DCT approaches can improve oncology trials.

Many elements of DCTs can be utilized to improve oncology studies. Hybrid decentralized study approaches combine the best facets of traditional and decentralized designs, allowing for more frequent and better data to be collected while simultaneously providing a central experience for participants. Learn how these approaches can be put to good use in the oncology field in the available white paper.